Yu Liu

Dr. Yu Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
JNJiayida Nulali
Jiayida Nulali
MZMing Zhan
Ming Zhan
KZKaiwen Zhang
Kaiwen Zhang
PTPinghui Tu
Pinghui Tu
YLYu Liu
Yu Liu
HSHuai-Dong Song
Huai-Dong Song
The extracellular matrix (ECM) is made up of noncellular components that have special properties for influencing cell behavior and tissue structure. Small leucine-rich proteoglycans (SLRPs) are nonfibrillar ECM components that serve as structural scaffolds and signaling molecules. osteoglycin (OGN), a class III SLRP, is a ubiquitous ECM component that not only helps to organize the extracellular matrix but also regulates a number of important biological processes. As a glycosylated protein in the ECM, OGN was originally considered to be involved in fiber assembly and was reported to have a connection with fibrosis. In addition to these functions, OGN is found in a variety of cancer tissues and is implicated in cellular processes linked to tumorigenesis, including cell proliferation, invasion, metastasis, and epithelial-mesenchymal transition (EMT). In this review, we summarize the structure and functions of OGN as well as its biological and clinical importance in the context of fibrotic illness and tumorigenesis. This review aims to improve our understanding of OGN and provide some new strategies for the treatment of fibrosis and cancer.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
YLYu Liu
Yu Liu
KZKai Zhang
Kai Zhang
HGHuaqi Guo
Huaqi Guo
CZCuixia Zheng
Cuixia Zheng
Aims: To determine the dose–response relationship between physical activity (PA) and pulmonary rehabilitation among different COPD subtypes. Methods: Data from NHANES 2007 to 2012, 16338 participants were used for this analysis. Among these participants, 312 were mild COPD, 166 were moderate COPD, 973 were early COPD and 130 were COPD in young people. FEV1/preFEV1 was defined as the primary outcome indicator to characterize pulmonary rehabilitation. In addition, the dose-response relationship between the amount of PA and lung function recovery was assessed by restricted cubic spline (RCS) regression. Results: For mild COPD, 25.63 to 213.57 MET*h per week of PA could promote recovery of lung function, 153.77 MET*h per week is the optimal PA. 0-18.30 MET*h per week PA was beneficial to the rise of lung function for moderate COPD, with the increase of PA, the recovery level of FEV1/preFEV1 benefiting from PA decreases. Among patients with COPD in young people or early COPD, when the PA exceeded 41.49 or 41.31, lung function showed an increasing trend. After sex or age stratification, we also obtained instructive conclusions. Besides, among US adults, only 39.9% mild COPD patients and 41.1% moderate COPD patients met the reasonable range of PA. Conclusion: The contribution of PA to lung function in COPD patients depends on disease severity, age and sex, and it is inaccurate to advocate for more exercise.